Shares of USA-based AbbVie (NYSE: ABBV) closed up 2.33% at $91.93 on Friday, having hit a day high of $94.97, after the company post third-quarter 2017 financial results.
AbbVie posted revenues of $7 billion, a year-on-year rise of 8.8% and in line with the Zacks Equity Research and consensus Wall Street estimates.
The company’s net earnings rose 2.1% to $1.63 billion in the third quarter. AbbVie's third-quarter earnings came in at $1.41 per share, beating the Zacks consensus estimate of $1.39.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze